M

Active Director Director DIN 07301121
DIN 07301121 First appointment Oct 2015 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2015
Shareholding value •••• Premium profile

About Maheepal

Data last updated:

Maheepal is a Director at Alleviate Pharmaceuticals Private Limited (since 2015). The company operates in Pharma. Alleviate Pharmaceuticals Private Limited reported revenue of ₹1.02 Cr (FY 2025).

DIN 07301121
Primary Designation Director
Industry Pharma
First Appointment 08 Oct 2015
Oldest Company Age 11 yrs
Largest company Alleviate Pharmaceuticals Private Limited · ₹1.02 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director08 Oct 20152015₹1.02 Cr (FY 2025)Active

Board colleagues of Maheepal

NameDINCompanyDesignation
Sanjiv Kumar07048016Alleviate Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Alleviate Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Maheepal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Maheepal

Maheepal currently holds 1 directorship: Alleviate Pharmaceuticals Private Limited (Director, since 08 Oct 2015, revenue ₹1.02 Cr (FY 2025)).

Maheepal was first appointed on 08 Oct 2015 as Director at Alleviate Pharmaceuticals Private Limited.

The current boards of Maheepal's companies include Sanjiv Kumar (Alleviate Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available